InsiderTrades

Form 4 for NTLA Intellia Therapeutics, Inc.

Accepted 2024-01-03 00:00:00 ET · period of report 2024-01-01 · accession 0000950170-24-001197 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-01-03 2024-01-01 NTLA LEONARD JOHN M Pres, CEO, Dir M - OptEx — +7,848 865.7K +0.9% —
D 2024-01-03 2024-01-01 NTLA LEONARD JOHN M Pres, CEO, Dir M - OptEx $0.00 -7,848 7,850 -50% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-01-01 M A 7,848 — 865,709 D — — (F1) Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
2 Derivative Restricted Stock Unit 2024-01-01 M D 7,848 $0.00 7,850 D — · 2024-01-01 to 2031-03-02 7,848 Common Stock (F1) Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. (F3) On March 3, 2021, the reporting person was granted 31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.